In June 2020, the Medsintez plant entered an agreement to join the Bioorganika Consortium of the Center for the National Technological Initiative of the Federal State Budgetary Institution ‘Institute of Bioorganic Chemistry named after Academicians M. M. Shemyakin and Yu. A. Ovchinnikov’ of the Russian Academy of Sciences (IBCh RAS).
Bioorganika Consortium is a partnership of educational and research institutions with high-tech companies. It aims to create advanced products and technologies which connect scientific results with the existing demands of research markets in order to boost the efficiency of the country’s economy and increase the duration and quality of life of the population.
As part of the Consortium, the Medsintez plant is going to develop new pharmaceutical technologies on its own premises. Today, such projects are under discussion as the production of an analogue of the human glucagon-like peptide, Lyraglutide, as well as VIII (antihemophilic globulin) and IX (Christmas factor) blood coagulation factors. Earlier, based on some IBCh RAS developments, the plant launched the production of analog forms of insulin required to treat type 1 diabetes, such as RosinsulinAspart and RosinsulinGlargin. Today, all production facilities of the plant are equipped with the cutting-edge, high-tech equipment, which enables the full cycle of research and development of synthetic and biotechnological medications and their dosage forms.
The Medsintez plant is a leading Russian pharmaceutical enterprise providing international-grade products, operating its own research labs and implementing the import-substitution policy. Joining the Consortium will enable it to contribute to increasing the duration and quality of life of the population, particularly by combining scientific, technological, organizational and managerial skills of the Consortium’s participants. For many years, the Medsintez plant has been working with major international pharmaceutical companies such as Bayer, STADA and iVFarma. Also, on its premises, such regional associations were established as the Ural Biomedical Cluster and the Association of Medical and Pharmaceutical Manufacturers of the Sverdlovsk Region. The plant contributed a lot to the accumulation of the region’s scientific, innovative, industrial, commercial and human potential within these organizations with the intention to Implement, particularly on the premises of the Medsintez plant, a suite of biotechnological projects.